OptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired Event
OptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired Event
Virtual event takes place December 1, 2022
虛擬活動將於2022年12月1日舉行
ROCHESTER, Mich., Oct. 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp (the "Company") (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the third annual Innovate4Outcomes® event co-sponsored by Melinta Therapeutics. This virtual event will take place on December 1, 2022. The sponsors are inviting participation from healthcare providers, pharmaceutical and medical technology manufacturers, healthcare marketing and advertising agencies, and others in the life sciences industry.
密歇根州羅切斯特,2022年10月20日(Global Newswire)--OPTIMIZERX公司(“公司”)(納斯達克:OPRX)是幫助患者開始並繼續接受治療的護理點式技術解決方案的領先提供商,今天宣佈了第三屆年度Innovate4Outcome®活動由梅林塔治療公司共同贊助。這一虛擬活動將於2022年12月1日舉行。贊助商邀請醫療保健提供者、製藥和醫療技術製造商、保健營銷和廣告機構以及生命科學行業的其他人蔘與。
Innovate4Outcomes is a design-thinking, half-day event that brings together those interested in cross-industry collaboration to brainstorm potential pathways to reduce the threat of systemic healthcare challenges in the US. This year's challenge has been identified by the World Health Organization as one of the ten most pressing current global health challenges: Antimicrobial Resistance (AMR). AMR has many facets which are aggravated by siloed care delivery pathways and social issues, among them treatment resistance, challenges in developing new therapies, provider education and health equity. A recent study published in The Lancet estimated that there were approximately 5 million global deaths associated with bacterial AMR in 2019, in addition to numerous other harmful impacts on human health and longevity.
Innovate4Outcome是一個具有設計思維的半天活動,將那些對跨行業合作感興趣的人聚集在一起,集思廣益,討論減少美國系統性醫療挑戰威脅的潛在途徑。今年的挑戰已被世界衞生組織確定為當前十大最緊迫的全球衞生挑戰之一:抗菌素耐藥性。AMR有許多方面,由於孤立的護理提供途徑和社會問題而加劇,其中包括治療阻力、開發新療法的挑戰、提供者教育和衞生公平。最近發表在《紐約時報》的一項研究柳葉刀據估計,2019年全球約有500萬人死於細菌性AMR,此外還有對人類健康和壽命的許多其他有害影響。
"We're delighted to co-sponsor this event with OptimizeRx," said Matthew Balogh, Head of Digital Marketing, Melinta Therapeutics. "AMR is a far-reaching health concern that will require new thinking to address, and Innnovate4Outcomes allows the healthcare community to come together and leverage their own varied backgrounds and experiences to add to the conversation."
Melinta治療公司數字營銷主管Matthew Balogh説:“我們很高興與OPTIMIZERx共同贊助這次活動。AMR是一個影響深遠的健康問題,需要新的思維來解決,而Innnovate4Outcome允許醫療保健社區走到一起,利用他們自己的不同背景和經驗來增加對話。“
On the day of the event, registrants will be divided into teams and will learn which of three systemic healthcare challenges related to AMR they will be assigned. Six teams, two for each challenge, will work together to envision future approaches to this significant health concern. Teams will then pitch their ideas to a panel of judges, and OptimizeRx will invest in the winning concept with the aim of creating a business case for further development.
在活動當天,註冊者將被分成幾個小組,並將瞭解與AMR相關的三個系統性醫療挑戰中的哪一個將被分配給他們。六個團隊,每個挑戰兩個,將共同努力,設想未來解決這一重大健康問題的方法。然後,團隊將向評委小組推介他們的想法,OPTIMIZERx將投資於獲勝的概念,目的是創造一個進一步發展的商業案例。
"Our annual design-thinking in healthcare event, Innovate4Outcomes, speaks to the visionary approach we take every day in working with our industry colleagues to improve therapy awareness, access, and adherence for patients," said Maria Cipicchio, SVP of Marketing and Communications, OptimizeRx. "Global health challenges like AMR take creative approaches to problem-solving, and we hold this annual event to envision a better future state of healthcare. We're delighted to be in a position this year to allow the opportunity to extend ongoing support to investigate whether we can bring the winning idea to life."
OPTIMIZERx營銷和傳播高級副總裁Maria Cipicchio説:“我們在醫療保健領域的年度設計思考活動Innovate4Outcome表明,我們每天都在與行業同行合作,提高患者的治療意識、獲取途徑和依從性,這表明我們採取了富有遠見的方法。像AMR這樣的全球健康挑戰採取創造性的方法來解決問題,我們舉辦這一年度活動是為了展望更好的未來醫療保健狀況。我們很高興今年能夠有機會提供持續的支持,以調查我們是否能夠將獲勝的想法變成現實。
The event is free, and invitations are required for event access. Visit this link to request an invitation.
活動是免費的,需要邀請才能進入活動。訪問此鏈接以請求邀請。
About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through the most intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications.
關於最佳選擇
OPTIMIZERx提供一流的健康技術,使生命科學組織、醫療保健提供者和患者在整個患者護理過程中的關鍵時刻能夠以護理為重點進行接觸。OPTIMIZERx通過嵌入在專有數字護理點網絡中的最智能技術平臺,連接了超過60%的美國醫療保健提供者和數百萬患者,幫助患者開始並持續服藥。
For more information, follow the Company on Twitter, LinkedIn, or visit .
有關更多信息,請在Twitter、LinkedIn或訪問上關注該公司。
About Melinta Therapeutics
Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes six commercial-stage products: Baxdela® (delafloxacin), Kimyrsa® (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), TOPROL-XL® (metoprolol succinate) and Vabomere® (meropenem and vaborbactam). With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that's how we make the most meaningful impact. At Melinta, we're visionaries dedicated to innovation while staying grounded in what matters most: patients. For additional information, including product and respective important safety information, please visit our website.
關於梅林塔治療公司
Melinta Treateutics,LLC為受到急性和危及生命的疾病影響的人提供創新的治療方法。我們的產品組合目前包括六個商業階段的產品:巴斯德拉®(德拉氟沙星)、基米莎®(奧立班)、注射用米諾辛®(米諾環素)、奧貝替夫®(奧立萬)、託普洛爾-XL®(美託洛爾琥珀酸酯)和Vabomere®(美羅培南和瓦博巴坦)。憑藉對提供者和他們所服務的患者的無與倫比的承諾,我們努力確保所有需要我們治療的人都能接受治療。我們專注於擴大我們的產品組合,為有未得到滿足的需求的患者提供服務,因為這是我們產生最有意義影響的方式。在梅林塔,我們是致力於創新的遠見卓識者,同時腳踏實地地關注最重要的事情:患者。欲瞭解更多信息,包括產品和各自的重要安全信息,請訪問我們的網站。
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates", "believes", "estimates", "expects", "forecasts", "intends", "plans", "projects", "targets", "designed", "could", "may", "should", "will" or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company's growth, business plans and future performance. These forward-looking statements are based on the Company's current expectations and assumptions regarding the Company's business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
關於前瞻性陳述的重要警告
本新聞稿包含符合1995年私人證券訴訟改革法的前瞻性陳述。諸如“預期”、“相信”、“估計”、“預期”、“預測”、“打算”、“計劃”、“項目”、“目標”、“設計”、“可能”、“可能”、“應該”、“將會”或其他類似的詞語和表述旨在識別這些前瞻性表述。除有關歷史事實的陳述外,所有反映公司對未來的預期、假設、預測、信念或意見的陳述均為前瞻性陳述,包括但不限於與公司增長、業務計劃和未來業績有關的陳述。這些前瞻性陳述是基於公司目前對公司業務、經濟和其他未來狀況的預期和假設。除非適用法律另有要求,否則公司不會因為新信息、未來事件或其他原因而公開更新或修改任何前瞻性陳述。前瞻性陳述本身就會受到風險和不確定性的影響,其中一些風險和不確定性是無法預測或量化的。未來的事件和實際結果可能與前瞻性陳述中陳述的、預期的或潛在的大不相同。受前瞻性陳述影響的風險和不確定因素包括但不限於政府監管、競爭的影響,以及公司在截至2021年12月31日的財政年度的Form 10-K年度報告、隨後的Form 10-Q季度報告以及提交給證券交易委員會的其他文件中總結的其他風險。
OptimizeRx Contact
Andy D'Silva, SVP Corporate Finance
adsilva@optimizerx.com
OPTIMIZERx聯繫人
安迪·德席爾瓦,公司財務高級副總裁
郵箱:adsilva@Optimizerx.com
Media Relations Contact
Kimberley Sirk, Media Relations Manager
ksirk@optimizerx.com
媒體關係聯繫人
媒體關係經理金伯利·瑟克
郵箱:ksirk@Optimizerx.com
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
投資者關係聯繫人
阿什利·羅賓遜
生活科學顧問有限責任公司
郵箱:arr@lifescivisors.com
譯文內容由第三人軟體翻譯。